机构

• 上海药物研究所 [69]

采集方式

• OAI收割 [69]

内容类型

• 期刊论文 [67]
• 会议论文 [2]

发表日期

• 2024 [1]
• 2023 [5]
• 2022 [3]
• 2021 [6]
• 2020 [2]
• 2019 [3]
• 更多

学科主题

筛选

浏览/检索结果: 共69条，第1-10条 帮助 限定条件 专题：上海药物研究所    第一署名单位    第一作者单位    通讯作者单位     条数/页： 5101520253035404550556065707580859095100 排序方式： 请选择提交时间升序提交时间降序发表日期升序发表日期降序题名升序题名降序作者升序作者降序 A novel strategy for treating oncogene-mutated tumors by targeting tumor microenvironment and synergistically enhancing anti-PD-1 immunotherapy 期刊论文  OAI收割 CANCER COMMUNICATIONS, 2024, 页码: 5 作者:  Liu, Yingqiang;  Tong, Linjiang;  Zhang, Mengge;  Zhang, Qi;  Liu, Qiupei   |  收藏  |  浏览/下载：13/0  |  提交时间：2024/03/13 Preclinical and early clinical studies of a novel compound SYHA1813 that efficiently crosses the blood-brain barrier and exhibits potent activity against glioblastoma 期刊论文  OAI收割 ACTA PHARMACEUTICA SINICA B, 2023, 卷号: 13, 期号: 12, 页码: 4748-4764 作者:  Liu, Yingqiang;  Zhan, Zhengsheng;  Kang, Zhuang;  Li, Mengyuan;  Lv, Yongcong   |  收藏  |  浏览/下载：9/0  |  提交时间：2024/01/26 Small molecule inhibitor  Tumor microenvironment  Immune-checkpoint  immune-deficient mouse models  including temozolomide (TMZ) insensitive tumors. Notably   Impact of SARS-CoV-2 envelope protein mutations on the pathogenicity of Omicron XBB 期刊论文  OAI收割 CELL DISCOVERY, 2023, 卷号: 9, 期号: 1, 页码: 4 作者:  Wang, Yi;  Pan, Xiaoyan;  Ji, Hongying;  Zuo, Xiaoli;  Xiao, Geng-Fu   |  收藏  |  浏览/下载：18/0  |  提交时间：2023/10/17 A procedure for producing an anti-AXL nanobody in E. coli 期刊论文  OAI收割 PROTEIN EXPRESSION AND PURIFICATION, 2023, 卷号: 207, 页码: 106268 作者:  Lan, Zhongyun;  Li, Lingyun;  Sun, Yili;  Meng, Xiangjing;  Shi, Zhenzhong   |  收藏  |  浏览/下载：5/0  |  提交时间：2024/03/27 AXL  Nanobody  Expression  Purification   SYK-mediated epithelial cell state is associated with response to c-Met inhibitors in c-Met-overexpressing lung cancer 期刊论文  OAI收割 SIGNAL TRANSDUCTION AND TARGETED THERAPY, 2023, 卷号: 8, 期号: 1, 页码: 13 作者:  Zhou, Ji;  Zhang, Xu-Chao;  Xue, Shan;  Dai, Mengdi;  Wang, Yueliang   |  收藏  |  浏览/下载：12/0  |  提交时间：2023/10/17 Discovery of HCD3514 as a potent EGFR inhibitor against C797S mutation in vitro and in vivo 期刊论文  OAI收割 JOURNAL OF CANCER, 2023, 卷号: 14, 期号: 1, 页码: 152-162 作者:  Lai, Mengzhen;  Zhang, Tao;  Chen, Hao;  Song, Peiran;  Tong, Linjiang   |  收藏  |  浏览/下载：80/0  |  提交时间：2023/04/10 fourth-generation EGFR inhibitor  EGFRC797S mutation  NSCLC  drug resistance  small molecular inhibitor   Construction of stable membranal CMTM6-PD-L1 full-length complex to evaluate the PD-1/PD-L1-CMTM6 interaction and develop anti-tumor anti-CMTM6 nanobody 期刊论文  OAI收割 ACTA PHARMACOLOGICA SINICA, 2022, 页码: 10 作者:  Jia, Xiao-min;  Long, Yi-ru;  Yu, Xiao-lu;  Chen, Run-qiu;  Gong, Li-kun   |  收藏  |  浏览/下载：17/0  |  提交时间：2023/04/10 cancer immunotherapy  CMTM6  CMTM6  PD-L1 complex  protein interactions  anti-CMTM6 nanobody   HER2/PD1 bispecific antibody in IgG4 subclass with superior anti-tumour activities 期刊论文  OAI收割 CLINICAL AND TRANSLATIONAL MEDICINE, 2022, 卷号: 12, 期号: 4, 页码: 6 作者:  Chu, Wendi;  Xu, Hui;  Wang, Yanfei;  Xie, Yongle;  Chen, Yi-Li   |  收藏  |  浏览/下载：18/0  |  提交时间：2022/06/15 SAF-248,a novel PI3Kδ-selective inhibitor,potently suppresses the growth of diffuse large B-cell lymphoma 期刊论文  OAI收割 ACTA PHARMACOLOGICA SINICA, 2022, 卷号: 43, 期号: 1, 页码: 209 作者:  Zhang Xi;  Duan Yuting;  Wang Yi;  Zhao Xingdong;  Sun Yiming   |  收藏  |  浏览/下载：9/0  |  提交时间：2023/05/22 PI3K6  PI3K/AKT/mTOR  diffuse large B-cell lymphoma  resistance  combination therapy   LS-106, a novel EGFR inhibitor targeting C797S, exhibits antitumor activities both in vitro and in vivo 期刊论文  OAI收割 CANCER SCIENCE, 2021, 页码: 12 作者:  Liu, Yingqiang;  Lai, Mengzhen;  Li, Shan;  Wang, Yanan;  Feng, Fang   |  收藏  |  浏览/下载：87/0  |  提交时间：2022/01/18 C797S  epidermal growth factor receptor  fourth-generation EGFR TKI  non-small cell lung cancer  osimertinib resistance